On January 13, 2015, Huanyu Dakang Medical News pharmaceutical giant Squibb Company ushered in a good start in 2015. The anti-cancer immunotherapy drug nivolumab developed by the company was approved last month under the trade name of Opdivo. In the first month of 2015, Opdivo heard good news again. In a comparative clinical study of umdlavuza wamaphaphu conducted by Squibb, Opdivo obtained new positive research data. In this clinical study involving 272 lung cancer patients, the researchers compared the efficacy of Opdivo with the current clinical standard therapy docetaxel, and the results proved the obvious advantage of this drug in the overall survival rate of patients. Reached the primary end point expected by previous researchers.
Opdivo is currently the most popular PD-1 drug. PD-1 is a cell cycle checkpoint protein. Its runaway causes isisu cells to escape immune monitoring in the body. According to the decision made by the FDA last month, Opdivo was approved for the treatment of melanoma (related reading: FDA approved Squibb PD-1 inhibitor Nivolumab (Opdivo) three months in advance, the same price as Keytruda) Similar drugs in this field are Keytruda from Merck. The results of Squibb ’s clinical research have made Opdivo the first PD-1 drug to treat lung cancer. More importantly, this result will help Squibb to lead its competitors in PD-1 drug research. Pharmaceutical companies currently active in this area include biomedical giants such as Merck, Roche and AstraZeneca.
U-Squibb udalule ukuthi inkampani isithumele isicelo sika-Opdivo sokwelashwa kwezinkomba zomdlavuza wamaphaphu ku-FDA kanye nabaphathi bezemithi be-EU. Kunjalo, i-Squibb Company enesifiso sokuvelela ngeke nje yaneliseke ngomdlavuza wamaphaphu kanye ne-melanoma. Eqinisweni, i-Squibb okwamanje yenza izifundo ezingaphezu kuka-35 ze-Opdivo iyodwa noma ihlanganiswe neminye imithi yokwelapha izinhlobo ezahlukene zesimila. Ngokusho kwabahlaziyi, ukuthengiswa kwesikhathi esizayo kwe-Opdivo kuzofinyelela phezulu ku-5 billion US dollars.
Umdlavuza immunotherapy research that has emerged in recent years has brought new hope for humans to conquer the disease of cancer. Almost all biomedical giants are planning in this field, hoping to share a cake. However, it is not yet known who will be the biggest winner in this technological revolution.
Umbiko wesiNgisi onemininingwane:
Isidakamizwa sika-Bristol-Myers Squibb's ($ BMY) esivelele se-immuno-o ncology i-nivolumab, esigunyazwe ngenyanga edlule njengo-Opdivo, sithole impumelelo emangazayo ovivinyweni lomdlavuza wamaphaphu osekuhambe isikhathi sakamuva, lwaqinisa okulindelekile ekuthengisweni kwe-pio yokwelashwa.
Ocwaningweni lweziguli ezingama-272 oluxabanisa u-Opdivo nombulali ojwayelekile womdlavuza, i-docetaxel ebulala umdlavuza, idemo yezidakamizwa iBristol-Myers iveze ukusinda okuphezulu kangaka uma kuqhathaniswa nengalo yokulawula okwaze kwafinyelela isiphetho sayo ngaphambi kwesikhathi esimisiwe, okuholele ekutheni kunconywe ikomidi elihlola imininingwane yocwaningo. ucwaningo lunqanyulwe kusenesikhathi. I-Bristol-Myers manje imema iziguli eziseqenjini le-docetaxel ukuthi zingene ku-Opdivo ngocwaningo olunelebula evulekile.
Ukwelashwa kukaBristol-Myers kuklanyelwe ukuqinisa ukuhlasela kwamasosha omzimba kumathumba ngokuvala indlela ebizwa ngokuthi i-PD-1, okuthi, iyekwa ingahloliwe, ivumele amangqamuzana omdlavuza ukuthi adlule ngaphandle kokubonwa izivikelo zemvelo zomzimba. Njenge-Keytruda kaMerck ($ MRK) efanayo, u-Opdivo wathola imvume ye-FDA ngonyaka odlule njengokwelapha i-melanoma, kodwa umuthi kaBristol-Myers uzimele wodwa kumdlavuza wamaphaphu, njengoba impumelelo yawo yakamuva yomtholampilo iphawula okokuqala ngqa ukuthi i-PD-1 inhibitor yenza inzuzo yokusinda ngokumelene nalesi sifo, kusho inkampani.
Opdivo’s particular promise in umdlavuza wamaphaphu weselula ongewona omncane has led analysts to pencil it in as the most commercially promising among therapies that block PD-1 and the related PD-L1, putting Bristol-Myers ahead of Merck, Roche ($ RHHBY), AstraZeneca ($ AZN) and others. Analysts figure Opdivo will bring in peak sales of around $ 5 billion, and Leerink’s Seamus Fernandez believes the treatment’s potential in lung cancer will take it as high as $ 7.3 billion by 2020. The entire class of therapies is expected to bring in a bout $ 35 billion a year.
UBristol-Myers ufake izicelo zomdlavuza wamaphaphu e-US naseYurophu ku-Opdivo kumdlavuza wamaphaphu, elindele ukwandisa ukusetshenziswa komuthi ngokuhamba kwesikhathi kulo nyaka.
Like its competitors, Bristol-Myers has mounted an expansive R & D program for its PD-1 candidate, running more than 35 trials in total that test Opdivo alone or as part of a cocktail in renal cell carcinoma, umdlavuza wekhanda nentamo, glioblastoma, Non-Hodgkin lymphoma and other cancers.
